Century Therapeutics (IPSC) Stock Analysis & AI Equity Report
Century Therapeutics (IPSC) overview
Century Therapeutics (IPSC) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 109m and operating profit of USD -17.3m; the year-end share price was 1.00 USD and market capitalisation was USD 87.1m. Century Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Century Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Century Therapeutics
Century Therapeutics is a biotechnology company developing allogeneic cell therapies using induced pluripotent stem cells. Its programs include beta islet cells, engineered T cells, and natural killer cells aimed at conditions including type 1 diabetes, other autoimmune diseases, and cancer. The company uses genetic editing and its Allo-Evasion technology in developing potential off-the-shelf therapies.
Generate the Century Therapeutics report
Century Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Century Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Century Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.